SCHEMBL29964205

SCHEMBL29964205

COCCN1CCC(OC)(c2ccc(-c3cc(-c4ccc5c(c4)CCNC5=O)c(N)nc3F)cc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 7/20 0.38
MAPK1 P28482 1/20 0.36
MAPK9 P45984 1/20 0.36
PARP10 Q53GL7 4/20 0.36
PARP11 Q9NR21 4/20 0.36
BACE1 P56817 1/20 0.34
CDK4 P11802 2/20 0.34
CCND1 P24385 2/20 0.34
CCND3 P30281 2/20 0.34
CDK6 Q00534 2/20 0.34
CCNT1 O60563 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CDK7 P50613 1/20 0.33
CDK9 P50750 1/20 0.33
CCNH P51946 1/20 0.33
MNAT1 P51948 1/20 0.33
PRKACA P17612 1/20 0.33
PRKACG P22612 1/20 0.33
PRKACB P22694 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29964206 0.92 MAPKAPK2 (0.38) MAPKAPK2MAPK1MAPK9PARP10PARP11
SCHEMBL29963920 0.91 MAPKAPK2 (0.38) MAPKAPK2MAPK1MAPK9PARP10PARP11
SCHEMBL29964188 0.87 MAPKAPK2 (0.41) MAPKAPK2MAPK1MAPK9PARP10PARP11
SCHEMBL29964606 0.86 PARP10 (0.41) MAPKAPK2MAPK1MAPK9PARP10PARP11
SCHEMBL29964856 0.86 MAPKAPK2 (0.41) MAPKAPK2MAPK1MAPK9PARP10PARP11
SCHEMBL31079058 0.85 HTR2A (0.43) MAPKAPK2MAPK1MAPK9PARP10PARP11
SCHEMBL29964028 0.84 MAPK1 (0.46) MAPKAPK2MAPK1MAPK9PARP10PARP11
SCHEMBL29963933 0.84 MAPK1 (0.42) MAPKAPK2MAPK1MAPK9PARP10PARP11
SCHEMBL29964850 0.83 MAPKAPK2 (0.39) MAPKAPK2MAPK1MAPK9PARP10PARP11
SCHEMBL29964207 0.83 MAPKAPK2 (0.40) MAPKAPK2MAPK1MAPK9PARP10PARP11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 US disclosed
WO-2022226668-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 MAPKAPK2 79/4885MAPK1 141/4885MAPK9 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.